Drug Profile
RO 14
Alternative Names: RO14Latest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Rovi
- Class Anticoagulants; Antithrombotics; Heparins; Low molecular weight heparins
- Mechanism of Action Factor Xa inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Thrombosis
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis in Spain (SC, Injection)
- 31 Dec 2007 Phase-I clinical trials in Thrombosis in Spain (SC)